Elo Mutual Pension Insurance Co Purchases 3,738 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Elo Mutual Pension Insurance Co lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 26.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,865 shares of the biopharmaceutical company’s stock after purchasing an additional 3,738 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Alnylam Pharmaceuticals were worth $8,146,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Thematics Asset Management bought a new stake in Alnylam Pharmaceuticals in the second quarter valued at $1,995,000. Mediolanum International Funds Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $11,389,000. Rakuten Investment Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $14,205,000. Generali Asset Management SPA SGR increased its position in shares of Alnylam Pharmaceuticals by 6,368.0% during the third quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock valued at $1,475,000 after buying an additional 3,184 shares during the period. Finally, Investment Management Corp of Ontario raised its stake in Alnylam Pharmaceuticals by 35.4% in the second quarter. Investment Management Corp of Ontario now owns 31,521 shares of the biopharmaceutical company’s stock worth $10,279,000 after buying an additional 8,244 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Pushkal Garg sold 2,242 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the transaction, the executive vice president directly owned 24,848 shares in the company, valued at $7,704,867.84. The trade was a 8.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jeffrey V. Poulton sold 2,242 shares of the stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the sale, the executive vice president owned 59,802 shares in the company, valued at approximately $18,543,404.16. This represents a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,578 shares of company stock valued at $12,416,105 over the last ninety days. Corporate insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $325.07 on Tuesday. The business has a fifty day moving average price of $358.89 and a 200-day moving average price of $417.95. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The company has a market capitalization of $43.11 billion, a PE ratio of 190.10 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.61). The firm had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same period last year, the company posted ($0.65) earnings per share. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on ALNY. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Stifel Nicolaus upped their price target on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Freedom Capital upgraded Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Leerink Partners dropped their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a report on Monday, December 15th. Finally, Royal Bank Of Canada decreased their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $477.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.